Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment

Qin Xia; Liqun Liu; Yang Li; Pei Zhang; Da Han; Lei Dong

doi:10.1080/07357907.2021.1952595

Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment

Qin Xia, Liqun Liu, Yang Li, Pei Zhang, Da Han, Lei Dong^*

^*Corresponding author for this work

Beijing Institute of Technology

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.

Original language	English
Pages (from-to)	627-644
Number of pages	18
Journal	Cancer Investigation
Volume	39
Issue number	8
DOIs	https://doi.org/10.1080/07357907.2021.1952595
Publication status	Published - 2021

Keywords

Glioma stem cells
drug resistance
glioblastoma
targeted therapy
temozolomide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2021.1952595

Cite this

@article{38a1b66a66554e1b8f42c052871ba11a,

title = "Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment",

abstract = "Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.",

keywords = "Glioma stem cells, drug resistance, glioblastoma, targeted therapy, temozolomide",

author = "Qin Xia and Liqun Liu and Yang Li and Pei Zhang and Da Han and Lei Dong",

note = "Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/07357907.2021.1952595",

language = "English",

volume = "39",

pages = "627--644",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment

AU - Xia, Qin

AU - Liu, Liqun

AU - Li, Yang

AU - Zhang, Pei

AU - Han, Da

AU - Dong, Lei

PY - 2021

Y1 - 2021

N2 - Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.

AB - Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.

KW - Glioma stem cells

KW - drug resistance

KW - glioblastoma

KW - targeted therapy

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85110798309&partnerID=8YFLogxK

U2 - 10.1080/07357907.2021.1952595

DO - 10.1080/07357907.2021.1952595

M3 - Review article

C2 - 34254870

AN - SCOPUS:85110798309

SN - 0735-7907

VL - 39

SP - 627

EP - 644

JO - Cancer Investigation

JF - Cancer Investigation

IS - 8

ER -

Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this